Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

106.79 +2.19 (+2.09%)

Streaming Delayed Price Updated: 11:33 AM EDT, Jul 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

My Top 3 Stocks to Buy in May ↗

May 07, 2026

Forget "sell in May and go away." These stocks are good picks to buy and hold.

Via The Motley Fool

Topics Earnings

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗

May 06, 2026

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.

Via Benzinga

Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Rhythm (RYTM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗

May 05, 2026

It released an encouraging quarterly earnings report and business update before market open.

Via The Motley Fool

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗

May 05, 2026

Via Chartmill

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗

February 26, 2026

Via Chartmill

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗

January 09, 2026

Via Stocktwits

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...

Via Finterra

Topics Economy Intellectual Property

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...

Via MarketMinute

Topics Intellectual Property

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Rhythm Pharmaceuticals's Earnings: A Preview ↗

November 03, 2025

Via Benzinga

Is This Weight Loss Drug Stock a Buy After a New Approval? ↗

March 31, 2026

This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?

Via The Motley Fool

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharma (RYTM) Earnings Call Transcript ↗

February 26, 2026

Rhythm Pharma (RYTM) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

These stocks all have catalysts on the way that could provide great news for investors.

Via The Motley Fool

Topics Artificial Intelligence

This High-Flying Growth Stock Is Hiding in Plain Sight ↗

February 02, 2026

This biotech stock is flying under the radar for many investors, but Wall Street loves it.

Via The Motley Fool

The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning

December 30, 2025

As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Topics ETFs Economy World Trade

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗

December 11, 2025

The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Via Stocktwits

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

December 10, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

These stocks are moving in today's after hours session ↗

November 11, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗

November 08, 2025

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗

November 04, 2025

Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.